To assess whether IDO1 expression reflects general monocyte activation or represents a distinct feature of EBV-HLH, we analyzed its association with established activation markers (HLA-DR, CD163, and CX3CR1) using flow cytometry in a new validation cohort comprising IM and EBV-HLH samples. This evidence concerns the gene CD163 and hemophagocytic syndrome.